Implant placement in patients under treatment with rivaroxaban: A retrospective clinical study

Guido Galletti, Fortunato Alfonsi, Angelo Raffaele, Nicola Alberto Valente, Sibylle Chatelain, Roni Kolerman, Chiara Cinquini, Stefano Romeggio, Giovanna Iezzi, Antonio Barone

Research output: Contribution to journalArticlepeer-review


The management of patients under treatment with Direct Oral Anticoagulants (DOACs) has led clinicians to deal with two clinical issues, such as the hemorrhagic risk in case of non-interruption or the risk of thromboembolism in case of suspension of the treatment. The primary aim of this retrospective study was to evaluate the incidence of perioperative bleeding events and healing complications in patients who were under treatment with Rivaroxaban and who received dental implants and immediate prosthetic restoration. Patients treated with Rivaroxaban (Xarelto 20 mg daily) and who needed implant rehabilitation were selected. Four to six implants were placed in mandibular healed sites or fresh extraction sockets. All patients, in agreement with their physicians, interrupted the medication for 24 h and received implants and immediate restorations. Twelve patients and 57 implants were analyzed in the study. No major postoperative bleeding events were reported. Three patients (25%) presented slight immediate postoperative bleeding controlled with compression only. The implant and prosthetic survival rate were both 100% after 1 year. Within the limitations of this study, multiple implant placement with an immediate loading can be performed without any significant complication with a 24 h discontinuation of Rivaroxaban, in conjunction with the patient’s physician.

Original languageEnglish
Article number4607
Pages (from-to)1-13
Number of pages13
JournalInternational Journal of Environmental Research and Public Health
Issue number12
StatePublished - 2 Jun 2020


  • Anticoagulants
  • Immediate loading
  • Implant placement


Dive into the research topics of 'Implant placement in patients under treatment with rivaroxaban: A retrospective clinical study'. Together they form a unique fingerprint.

Cite this